Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar, adalimumab) in Asia

Alvotech Signs an Exclusive License Agreement with DKSH for AVT02 (biosimilar, adalimumab) in Asia

Shots:

  • Alvotech will be responsible for the development and supply of AVT02 in selected APAC market, while DKSH will be responsible for the registration and commercialization of the therapy
  • The alliance allows the Alvotech to gain access to DKHS’s commercial expertise, which will aid patients to get benefited with high-quality biosimilar therapies
  • AVT02 is a biosimilar referencing AbbVie’s Humira, which is indicated to treat RA, AS, PP, PsO, UC & CD with its anticipated regulatory filing to the EMA & the US FDA in H2’20

Click here ­to­ read full press release/ article | Ref: Alvotech | Image: Contract Pharma